AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

An Effective Anti-Cancer Combination Therapy, with Substantially Reduced Side Effects

Technology Application

Anti-cancer combination therapy

Detailed Technology Description

Researchers at the University of California, Davis have developed an effective local therapeutic strategy with substantially reduced side effects using a combination of doxorubicin (Dox) and copper (II). Cu-liposomes were loaded with Dox up to a maximum concentration of 0.6mg-drug/mg-lipid. UC Davis researchers have studied the efficacy of Cu-Dox liposomes and optimized the treatment strategy using the highly invasive and metastatic Met-1 tumor, a syngeneic model of human breast carcinoma. All animals receiving the combined therapy survived throughout the 28 day course of treatment and did not show any side effects. Significant tumor regression was accomplished by combining Cu-Dox liposomes with another drug and tumor insonation.

Supplementary Information

Patent Number: WO2011109334A3
Application Number: WO2011US26592A
Inventor: FERRARA, Katherine, W. | KHEIROLOMOOM, Azadeh
Priority Date: 1 Mar 2010
Priority Number: WO2011109334A3
Application Date: 1 Mar 2011
Publication Date: 1 Mar 2012
IPC Current: A61K0009127 | A61K00317042 | A61K003300 | A61K004748 | A61P003500
Assignee Applicant: The Regents of the University of California
Title: LOCALIZATION OF AGENTS AT A TARGET SITE WITH A COMPOSITION AND AN ENERGY SOURCE | LOCALISATION D'AGENTS DANS UN SITE CIBLE COMPORTANT UNE COMPOSITION ET UNE SOURCE D'ÉNERGIE
Usefulness: LOCALIZATION OF AGENTS AT A TARGET SITE WITH A COMPOSITION AND AN ENERGY SOURCE | LOCALISATION D'AGENTS DANS UN SITE CIBLE COMPORTANT UNE COMPOSITION ET UNE SOURCE D'ÉNERGIE
Summary: For localized delivery of an agent to a target site for treating tumor (claimed); for treating other diseases e.g. diabetes, infection, inflammation, cardiovascular diseases including ischemic conditions, cardiopathies, and brain diseases, coronary artery disease (CAD); atherosclerosis; thrombosis; restenosis; vasculitis including autoimmune and viral vasculitis such as polyarteritis nodosa, Churg-Strauss syndrome, Takayasu's arteritis, Kawasaki disease and Rickettsial vasculitis; atherosclerotic aneurisms; myocardial hypertrophy; congenital heart diseases (CHD); ischemic heart disease and anginas; acquired valvular/endocardial diseases; primary myocardial diseases including myocarditis; arrhythmias; and transplant rejection.
Novelty: Localized delivery of an agent to a target site for treating e.g. tumor involves administering a composition comprising agent-transition metal complex to subject having target site; and irradiating target site with energy source

Industry

Biomedical

Sub Group

Medical Composition

Application No.

9844656

Others

ABSTRACT

An image guided effective anti-cancer therapy, with greatly reduced side effects, using liposomal copper doxorubicin.

Features/Benefits

Reduced side effects
Enhanced anti-tumor activity when combined with entire tumor insonation

Additional Technologies by these Inventors

Targeted Delivery to the Heart Endothelium

Tech ID/UC Case

20801/2010-482-0

Related Cases

2010-482-0

Country/Region

USA

For more information, please click Here